Success Metrics

Clinical Success Rate
78.8%

Based on 230 completed trials

Completion Rate
79%(230/292)
Active Trials
23(6%)
Results Posted
48%(110 trials)
Terminated
62(17%)

Phase Distribution

Ph phase_3
51
14%
Ph not_applicable
26
7%
Ph phase_2
137
37%
Ph phase_4
64
17%
Ph early_phase_1
6
2%
Ph phase_1
76
20%

Phase Distribution

82

Early Stage

137

Mid Stage

115

Late Stage

Phase Distribution360 total trials
Early Phase 1First-in-human
6(1.7%)
Phase 1Safety & dosage
76(21.1%)
Phase 2Efficacy & side effects
137(38.1%)
Phase 3Large-scale testing
51(14.2%)
Phase 4Post-market surveillance
64(17.8%)
N/ANon-phased studies
26(7.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

74.7%

230 of 308 finished

Non-Completion Rate

25.3%

78 ended early

Currently Active

23

trials recruiting

Total Trials

371

all time

Status Distribution
Active(30)
Completed(230)
Terminated(78)
Other(33)

Detailed Status

Completed230
Terminated62
unknown31
Recruiting16
Withdrawn16
Active, not recruiting7

Development Timeline

Analytics

Development Status

Total Trials
371
Active
23
Success Rate
78.8%
Most Advanced
Phase 4

Trials by Phase

Early Phase 16 (1.7%)
Phase 176 (21.1%)
Phase 2137 (38.1%)
Phase 351 (14.2%)
Phase 464 (17.8%)
N/A26 (7.2%)

Trials by Status

suspended21%
terminated6217%
active_not_recruiting72%
recruiting164%
completed23062%
not_yet_recruiting72%
unknown318%
withdrawn164%

Recent Activity

Clinical Trials (371)

Showing 20 of 371 trialsScroll for more
NCT06997068Phase 2

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population

Recruiting
NCT07820891Phase 1

A Trial in Healthy Participants to Assess Drug Interaction Potential of BGB-43395

Not Yet Recruiting
NCT01356290Phase 2

Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors

Recruiting
NCT07804979Not Applicable

Comparison of Efficacy of Minocyclin and Celecoxib as Adjunctive Treatment in Treatment Resistant Cases of Major Depressive Disorder

Completed
NCT05756166Phase 1

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

Terminated
NCT06505187Phase 2

Celecoxib for ENT Pain Management

Recruiting
NCT06942039Early Phase 1

Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation

Recruiting
NCT07139405Phase 2

TriGlytza®-01 Versus Metformin in Overweight and Obese Adults With Type 2 Diabetes and Inadequate Glycaemic Control Despite Metformin Therapy

Not Yet Recruiting
NCT06076837Phase 1

The Seven Trial: Exploiting the Unfolded Protein Response

Terminated
NCT02885974Phase 1

Celecoxib With Chemotherapy in Localized, Muscle-Invasive Bladder Cancer

Completed
NCT07634094Phase 2

Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer

Not Yet Recruiting
NCT00159484Phase 1

Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer

Completed
NCT07597902Phase 2

SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction

Not Yet Recruiting
NCT01150045Phase 3

Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery

Completed
NCT07559682Phase 1

Efficacy of Selective COX-2 Inhibitors in Relieving Orthodontic Pain

Active Not Recruiting
NCT06245109Phase 4

Brain-Based and Clinical Phenotyping of Pain Pharmacotherapy in Knee Osteoarthritis

Recruiting
NCT02993029Not Applicable

99Tc-MDP Treatment for Knee Osteoarthritis

Recruiting
NCT06699966Phase 4

Stony Brook Medicine Anti-Inflammatory Trial

Not Yet Recruiting
NCT04765644Phase 4

Arginine Supplementation to Improve Cardiovascular and Endothelial Function After NSAID Treatment

Completed
NCT03818932Phase 2

Nonopioid Analgesia After Anterior Cruciate Ligament Reconstruction

Completed

Drug Details

Intervention Type
DRUG
Total Trials
371